Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.

Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A.

Front Oncol. 2020 Jan 10;9:1483. doi: 10.3389/fonc.2019.01483. eCollection 2019.

2.

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA.

J Thorac Oncol. 2020 Apr;15(4):618-627. doi: 10.1016/j.jtho.2019.12.109. Epub 2019 Dec 20.

PMID:
31870883
3.

Detection of Three Distinct Clonal Populations Using Circulating Cell Free DNA: A Cautionary Note on the Use of Liquid Biopsy.

Riedlinger GM, Jalloul N, Poplin E, Mehnert JM, Groisberg R, Khiabanian H, Ganesan S.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00193. Epub 2019 Jul 31. No abstract available.

4.

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.

Mehnert JM, Kaveney AD, Malhotra J, Spencer K, Portal D, Goodin S, Tan AR, Aisner J, Moss RA, Lin H, Bertino JR, Gibbon D, Doyle LA, White EP, Stein MN.

Cancer Chemother Pharmacol. 2019 Oct;84(4):899-907. doi: 10.1007/s00280-019-03919-x. Epub 2019 Aug 28.

PMID:
31463691
5.

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.

Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, Liu K, Hsu CP, Pickett CA, Mehnert JM.

EBioMedicine. 2019 Sep;47:89-97. doi: 10.1016/j.ebiom.2019.07.066. Epub 2019 Aug 10.

6.

A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors.

Stein MN, Goodin S, Gounder M, Gibbon D, Moss R, Portal D, Lindquist D, Zhao Y, Takebe N, Tan A, Aisner J, Lin H, Ready N, Mehnert JM.

Invest New Drugs. 2019 Aug 6. doi: 10.1007/s10637-019-00807-2. [Epub ahead of print]

PMID:
31388792
7.

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.

Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, Sharma A, Garbe C, Singh P, Mehnert JM.

Br J Cancer. 2019 Aug;121(5):417-420. doi: 10.1038/s41416-019-0530-6. Epub 2019 Jul 29.

8.

Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma.

Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA, Lattime EC.

Cancer Gene Ther. 2019 Jun 20. doi: 10.1038/s41417-019-0112-z. [Epub ahead of print]

9.

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A.

J Immunother Cancer. 2019 May 22;7(1):136. doi: 10.1186/s40425-019-0599-8.

10.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.

Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B.

BMC Cancer. 2019 Mar 4;19(1):196. doi: 10.1186/s12885-019-5380-3.

11.

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M.

Cancer Immunol Immunother. 2019 Apr;68(4):609-618. doi: 10.1007/s00262-018-02295-4. Epub 2019 Feb 5.

12.

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.

Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee KW, Kasturi V, Chin K, von Heydebreck A, Gulley JL.

J Immunother Cancer. 2019 Jan 16;7(1):12. doi: 10.1186/s40425-018-0459-y.

13.

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK.

J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.

PMID:
30557521
14.

Author Correction: Autophagy maintains tumour growth through circulating arginine.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD, White E.

Nature. 2019 Jan;565(7737):E3. doi: 10.1038/s41586-018-0815-6.

PMID:
30523330
15.

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, Matei D.

Gynecol Oncol. 2019 Feb;152(2):243-250. doi: 10.1016/j.ygyno.2018.11.017. Epub 2018 Dec 3.

PMID:
30522700
16.

Autophagy maintains tumour growth through circulating arginine.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD, White E.

Nature. 2018 Nov;563(7732):569-573. doi: 10.1038/s41586-018-0697-7. Epub 2018 Nov 14. Erratum in: Nature. 2018 Dec 6;:.

17.

Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.

Hurwitz ME, Markowski P, Yao X, Deshpande H, Patel J, Mortazavi A, Donadio A, Stein MN, Kelly WK, Petrylak DP, Mehnert JM.

Clin Genitourin Cancer. 2018 Dec;16(6):437-444.e6. doi: 10.1016/j.clgc.2018.07.021. Epub 2018 Jul 29.

PMID:
30177237
18.

Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.

Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH.

Cancer Res. 2018 Sep 15;78(18):5398-5407. doi: 10.1158/0008-5472.CAN-18-0316. Epub 2018 Jul 24.

19.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

20.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

21.

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL.

Cancer. 2018 May 1;124(9):2010-2017. doi: 10.1002/cncr.31293. Epub 2018 Feb 22.

22.

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Mehnert JM, Silk AW, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS.

Pigment Cell Melanoma Res. 2018 Jul;31(4):534-540. doi: 10.1111/pcmr.12694. Epub 2018 Apr 10.

23.

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.

Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S.

J Natl Cancer Inst. 2018 Mar 1;110(3):316-320. doi: 10.1093/jnci/djx213.

24.

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.

Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM.

Clin Cancer Res. 2017 Sep 1;23(17):4992-5002. doi: 10.1158/1078-0432.CCR-16-3066.

25.

The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN.

Clin Cancer Res. 2017 Sep 1;23(17):4970-4979. doi: 10.1158/1078-0432.CCR-16-3063.

26.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR.

J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.

PMID:
28837405
27.

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM.

J Clin Oncol. 2017 Dec 1;35(34):3823-3829. doi: 10.1200/JCO.2017.72.5069. Epub 2017 Aug 16.

PMID:
28813164
28.

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.

Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, Ganesan S.

Clin Cancer Res. 2017 Sep 15;23(18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. Epub 2017 May 24.

29.

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC.

J Clin Oncol. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. Epub 2017 May 10.

PMID:
28489510
30.

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.

Mehnert JM, Edelman G, Stein M, Camisa H, Lager J, Dedieu JF, Ghuysen AF, Sharma J, Liu L, LoRusso PM.

Invest New Drugs. 2018 Feb;36(1):36-44. doi: 10.1007/s10637-017-0467-7. Epub 2017 Apr 17.

PMID:
28417284
31.

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM.

Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22.

32.

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.

Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00146. Epub 2017 Dec 7.

33.

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A.

Eur J Cancer. 2016 Nov;67:46-54. doi: 10.1016/j.ejca.2016.07.018. Epub 2016 Sep 2.

34.

Biomarkers for Immunotherapy: Current Developments and Challenges.

Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM.

Am Soc Clin Oncol Educ Book. 2016;35:e493-503. doi: 10.14694/EDBK_160766.

35.

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S.

J Clin Invest. 2016 Jun 1;126(6):2334-40. doi: 10.1172/JCI84940. Epub 2016 May 9.

36.

Importance of including patients with comorbidities in clinical trials.

Spencer KR, Mehnert JM.

Lancet Oncol. 2016 Jan;17(1):17-8. doi: 10.1016/S1470-2045(15)00452-0. Epub 2015 Dec 23. No abstract available.

PMID:
26758750
37.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
38.

Mucosal Melanoma: Epidemiology, Biology and Treatment.

Spencer KR, Mehnert JM.

Cancer Treat Res. 2016;167:295-320. doi: 10.1007/978-3-319-22539-5_13. Review.

PMID:
26601869
39.

Autophagy, Metabolism, and Cancer.

White E, Mehnert JM, Chan CS.

Clin Cancer Res. 2015 Nov 15;21(22):5037-46. doi: 10.1158/1078-0432.CCR-15-0490. Review.

40.

Oncolytic virus immunotherapy for melanoma.

Dharmadhikari N, Mehnert JM, Kaufman HL.

Curr Treat Options Oncol. 2015 Mar;16(3):326. doi: 10.1007/s11864-014-0326-0. Review.

PMID:
25777572
41.

Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.

Higano CS, Berlin J, Gordon M, LoRusso P, Tang S, Dontabhaktuni A, Schwartz JD, Cosaert J, Mehnert JM.

Invest New Drugs. 2015 Apr;33(2):450-62. doi: 10.1007/s10637-015-0217-7. Epub 2015 Mar 7.

PMID:
25749986
42.

Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.

Xie X, Koh JY, Price S, White E, Mehnert JM.

Cancer Discov. 2015 Apr;5(4):410-23. doi: 10.1158/2159-8290.CD-14-1473. Epub 2015 Feb 11.

43.

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.

Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, Lawson D, Bartell H, Kudchadkar R, Gunter NT, Mehnert JM, Lipson EJ.

J Immunother Cancer. 2014 Oct 14;2(1):33. doi: 10.1186/s40425-014-0033-1. eCollection 2014.

44.

Co-culture systems of human sweat gland derived stem cells and peripheral nerve cells: an in vitro approach for peripheral nerve regeneration.

Mehnert JM, Kisch T, Brandenburger M.

Cell Physiol Biochem. 2014;34(4):1027-37. doi: 10.1159/000366318. Epub 2014 Sep 8.

45.

Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need.

Palyca P, Koshenkov VP, Mehnert JM.

Am Soc Clin Oncol Educ Book. 2014:e397-404. doi: 10.14694/EdBook_AM.2014.34.e397. Review.

46.

Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.

Teh JL, Shah R, Shin SS, Wen Y, Mehnert JM, Goydos J, Chen S.

Pigment Cell Melanoma Res. 2014 Jul;27(4):621-9. doi: 10.1111/pcmr.12237. Epub 2014 Apr 11.

47.

Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.

Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA.

Clin Cancer Res. 2014 Mar 15;20(6):1666-75. doi: 10.1158/1078-0432.CCR-13-2070. Epub 2014 Feb 3.

48.

Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.

Wen Y, Li J, Koo J, Shin SS, Lin Y, Jeong BS, Mehnert JM, Chen S, Cohen-Sola KA, Goydos JS.

Cancer Res. 2014 May 1;74(9):2499-509. doi: 10.1158/0008-5472.CAN-13-1531. Epub 2014 Feb 3.

49.
50.

Ipilimumab administration in patients with advanced melanoma and hepatitis B and C.

Sharma A, Thompson JA, Repaka A, Mehnert JM.

J Clin Oncol. 2013 Jul 20;31(21):e370-2. doi: 10.1200/JCO.2012.47.1946. Epub 2013 Jun 17. No abstract available.

PMID:
23775956

Supplemental Content

Loading ...
Support Center